Research suggests that new cancer treatments have played an especially important role in reducing mortality rates in certain cancers over the past several decades. Disruption to the industry from the COVID-19 pandemic threatens this progress.

Precision’s Joanna P. MacEwan and Ross Maclean use data from a study by Pfizer and PRECISIONheor to identify ways pharma can do its part to prevent further delays in oncology drug development and approval by leveraging the lessons learned from the COVID-19 vaccine development process.

Read the full article here!